NCT03484702 · OUTCOME
Change From Baseline in European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma · Source last updated 2024-12-27
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure MEAN
Unit Scores on a Scale
Interval / dispersion Standard Deviation
Time frame At baseline and Day 1, 29, 60, 90, 180, 270, 365, 545, and 730 post JCAR017 infusion. What was measured The EORTC QLQ-C30 consists of five functional scales (physical, role, emotional, cognitive, social), three symptom scales (fatigue, nausea/vomiting, pain), a global health status/health-related quality of life (HRQoL) scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). The questionnaire is scored on a 4-point Likert scale: 1 = not at all, 2 = a little, 3 = quite a bit, 4 = very much. The raw score is the average of the items contributing to the scale. The final scores are calculated via linear transformation of raw scores and range from 0 to 100. For functional scales higher scores indicate better QoL. For symptom scales and single items lower scores indicate fewer symptoms, i.e. better QoL. Baseline the last available recorded scores on or prior to the date of JCAR017 infusion. Only global health, fatigue, physical and cognitive functioning subscales were assessed.
Analysis population: All participants in the JCAR017-treated set with completed baseline questionnaires and with at least one completed post-baseline questionnaire.
Groups in this outcome Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy JCAR017 was infused at a dose of 100 x 10\^6 JCAR017-positive transfected viable T cells (50 × 10\^6 CD8+ CAR+ T cells and 50 × 10\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).
Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy JCAR017 was infused at a dose of 100 x 10\^6 JCAR017-positive transfected viable T cells (50 × 10\^6 CD8+ CAR+ T cells and 50 × 10\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).
Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 JCAR017 was infused at a dose of 100 x 10\^6 JCAR017-positive transfected viable T cells (50 × 10\^6 CD8+ CAR+ T cells and 50 × 10\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).
Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma JCAR017 was infused at a dose of 100 x 10\^6 JCAR017-positive transfected viable T cells (50 × 10\^6 CD8+ CAR+ T cells and 50 × 10\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).
Cohort 5: Primary Central Nervous System Lymphoma JCAR017 was infused at a dose of 100 x 10\^6 JCAR017-positive transfected viable T cells (50 × 10\^6 CD8+ CAR+ T cells and 50 × 10\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).
Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting JCAR017 was infused at a dose of 100 x 10\^6 JCAR017-positive transfected viable T cells (50 × 10\^6 CD8+ CAR+ T cells and 50 × 10\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 34 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 23 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 10 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 5 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 9
Reported measurements Global Health Status: Change from baseline Day 1 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 34 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 23 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 10 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 5 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 9
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy -4.41 17.070 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy -5.07 17.898 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 -6.67 10.244 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma -8.33 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma 8.33 25.685 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting -7.41 12.108 Not reported Not reported Not reported
Global Health Status: Change from baseline Day 29 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 33 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 19 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 10 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 4 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 9
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy -1.26 14.301 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 0.00 18.002 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 -4.17 17.236 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 0.00 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma 16.67 11.785 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting -1.85 14.299 Not reported Not reported Not reported
Global Health Status: Change from baseline Day 60 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 30 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 17 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 6 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 3 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 9
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 5.00 14.778 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 7.84 17.547 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 4.17 16.457 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 0.00 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma 13.89 26.788 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 9.26 8.784 Not reported Not reported Not reported
Global Health Status: Change from baseline Day 90 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 27 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 13 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 7 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 3 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 9
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 2.47 14.766 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 1.28 22.527 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 -5.95 17.817 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 0.00 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma 22.22 41.107 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 4.63 8.448 Not reported Not reported Not reported
Global Health Status: Change from baseline Day 180 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 12 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 8 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 7 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 3 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 6
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 6.94 13.685 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 1.04 23.332 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 -13.10 35.635 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma -16.67 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma 25.00 22.048 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 2.78 8.607 Not reported Not reported Not reported
Global Health Status: Change from baseline Day 270 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 12 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 6 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 5 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 3 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 5
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 6.25 20.140 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 9.72 9.742 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 -3.33 26.745 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 0.00 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma 25.00 22.048 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 3.33 9.501 Not reported Not reported Not reported
Global Health Status: Change from baseline Day 365 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 10 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 7 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 4 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 3 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 5
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy -6.67 20.337 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 3.57 11.664 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 -12.50 25.909 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 0.00 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma 30.56 26.788 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 3.33 7.454 Not reported Not reported Not reported
Global Health Status: Change from baseline Day 545 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 9 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 7 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 3 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 2 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 5
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy -6.48 18.530 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 3.57 26.726 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 -5.56 24.056 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 0.00 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma 0.00 47.140 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 1.67 9.129 Not reported Not reported Not reported
Global Health Status: Change from baseline Day 730 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 12 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 6 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 4 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 2 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 4
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy -11.11 12.975 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy -4.17 12.638 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 -6.25 7.979 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 0.00 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma 20.83 29.463 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting -2.08 21.916 Not reported Not reported Not reported
Physical Functioning: Change from baseline Day 1 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 34 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 23 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 10 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 5 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 9
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy -3.33 20.970 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy -6.09 21.074 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 -3.33 11.440 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma -6.67 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma -2.67 19.777 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting -3.70 14.948 Not reported Not reported Not reported
Physical Functioning: Change from baseline Day 29 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 33 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 19 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 10 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 5 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 9
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy -2.63 18.555 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy -4.21 10.706 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 -10.00 14.824 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 6.67 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma -8.33 16.667 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting -8.15 18.493 Not reported Not reported Not reported
Physical Functioning: Change from baseline Day 60 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 30 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 17 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 6 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 3 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 9
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 3.11 15.135 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy -0.39 21.275 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 -4.44 15.587 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 0.00 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma -2.22 10.184 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting -2.96 10.062 Not reported Not reported Not reported
Physical Functioning: Change from baseline Day 90 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 27 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 13 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 7 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 3 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 9
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 3.46 16.781 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 3.59 12.054 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 -5.71 11.174 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 6.67 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma 11.11 23.413 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting -0.74 18.692 Not reported Not reported Not reported
Physical Functioning: Change from baseline Day 180 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 12 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 8 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 7 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 3 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 6
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 7.78 12.975 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy -8.33 31.219 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 -5.71 19.024 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma -6.67 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma 15.56 27.756 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting -2.22 24.825 Not reported Not reported Not reported
Physical Functioning: Change from baseline Day 270 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 12 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 6 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 5 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 3 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 5
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 3.33 10.050 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 1.11 19.052 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 -2.67 22.410 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 6.67 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma 24.44 27.756 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting -6.67 31.972 Not reported Not reported Not reported
Physical Functioning: Change from baseline Day 365 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 10 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 7 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 4 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 3 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 5
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 0.67 16.163 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 0.95 16.069 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 -16.67 20.000 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 6.67 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma 22.22 26.943 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 5.33 11.926 Not reported Not reported Not reported
Physical Functioning: Change from baseline Day 545 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 9 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 7 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 3 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 2 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 5
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy -3.70 26.690 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy -1.90 19.135 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 -13.33 23.094 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 6.67 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma 13.33 47.140 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 9.33 11.155 Not reported Not reported Not reported
Physical Functioning: Change from baseline Day 730 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 12 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 6 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 4 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 2 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 4
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 1.11 15.785 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy -8.89 28.493 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 -3.33 8.607 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 6.67 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma 3.33 42.426 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting -3.33 11.547 Not reported Not reported Not reported
Cognitive Functioning: Change from baseline Day 1 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 34 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 23 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 10 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 5 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 9
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy -3.43 17.301 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy -3.62 17.376 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 -1.67 9.461 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 0.00 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma -3.33 13.944 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting -1.85 10.015 Not reported Not reported Not reported
Cognitive Functioning: Change from baseline Day 29 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 33 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 19 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 10 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 4 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 9
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy -2.53 16.203 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 3.51 14.250 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 3.33 13.147 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 0.00 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma 8.33 21.517 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting -7.41 12.108 Not reported Not reported Not reported
Cognitive Functioning: Change from baseline Day 60 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 30 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 17 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 6 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 3 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 9
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 2.78 12.444 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 0.98 10.978 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 0.00 27.889 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 0.00 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma 33.33 44.096 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting -1.85 13.029 Not reported Not reported Not reported
Cognitive Functioning: Change from baseline Day 90 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 27 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 13 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 7 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 3 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 9
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 0.00 13.074 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy -1.28 12.659 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 4.76 20.893 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 0.00 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma 11.11 19.245 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 0.00 8.333 Not reported Not reported Not reported
Cognitive Functioning: Change from baseline Day 180 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 12 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 8 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 7 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 3 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 6
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy -2.78 15.624 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy -2.08 5.893 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 11.90 20.893 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 0.00 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma 16.67 28.868 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting -5.56 8.607 Not reported Not reported Not reported
Cognitive Functioning: Change from baseline Day 270 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 12 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 6 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 5 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 3 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 5
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 0.00 22.473 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 0.00 0.000 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 3.33 13.944 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 0.00 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma 33.33 44.096 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 3.33 7.454 Not reported Not reported Not reported
Cognitive Functioning: Change from baseline Day 365 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 10 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 7 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 4 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 3 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 5
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy -11.67 22.292 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 0.00 0.000 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 -4.17 8.333 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 0.00 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma 22.22 38.490 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 6.67 9.129 Not reported Not reported Not reported
Cognitive Functioning: Change from baseline Day 545 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 9 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 7 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 3 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 2 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 5
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy -7.41 18.840 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 2.38 11.501 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 -5.56 19.245 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 0.00 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma -41.67 82.496 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 3.33 7.454 Not reported Not reported Not reported
Cognitive Functioning: Change from baseline Day 730 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 12 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 6 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 4 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 2 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 4
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy -1.39 18.060 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy -5.56 8.607 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 -4.17 15.957 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 0.00 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma -16.67 23.570 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting -4.17 8.333 Not reported Not reported Not reported
Fatigue: Change from baseline Day 1 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 34 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 23 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 10 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 5 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 9
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 1.63 26.959 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 1.45 16.173 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 3.33 20.320 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 0.00 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma -20.00 30.832 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 1.23 18.794 Not reported Not reported Not reported
Fatigue: Change from baseline Day 29 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 33 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 19 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 10 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 4 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 9
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 3.03 24.418 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 2.34 12.046 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 5.56 17.568 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma -11.11 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma -13.89 27.778 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 6.17 14.815 Not reported Not reported Not reported
Fatigue: Change from baseline Day 60 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 30 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 17 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 6 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 3 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 9
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy -9.63 18.623 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy -1.31 20.743 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 3.70 31.946 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 11.11 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma -14.81 35.717 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 0.00 17.568 Not reported Not reported Not reported
Fatigue: Change from baseline Day 90 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 27 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 13 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 7 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 3 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 9
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy -4.53 19.795 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy -4.27 17.881 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 4.76 35.635 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma -11.11 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma -37.04 12.830 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting -3.70 22.906 Not reported Not reported Not reported
Fatigue: Change from baseline Day 180 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 12 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 8 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 7 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 3 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 6
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy -8.33 21.254 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 2.78 34.503 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 -4.76 38.946 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 22.22 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma -37.04 23.130 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 0.00 33.702 Not reported Not reported Not reported
Fatigue: Change from baseline Day 270 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 12 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 6 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 5 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 3 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 5
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy -9.26 15.594 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 0.00 22.222 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 -6.67 14.907 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma -11.11 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma -29.63 42.066 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting -2.22 34.605 Not reported Not reported Not reported
Fatigue: Change from baseline Day 365 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 10 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 7 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 4 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 3 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 5
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy -3.33 14.861 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy -4.76 20.141 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 13.89 33.179 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma -11.11 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma -44.44 22.222 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting -13.33 14.487 Not reported Not reported Not reported
Fatigue: Change from baseline Day 545 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 9 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 7 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 3 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 2 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 5
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 4.94 25.526 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy -1.59 19.698 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 -3.70 27.962 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma -11.11 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma -5.56 23.570 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting -11.11 15.713 Not reported Not reported Not reported
Fatigue: Change from baseline Day 730 Analysis denominator · Participants
Group Source count Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 12 Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 6 Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 4 Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma 1 Cohort 5: Primary Central Nervous System Lymphoma 2 Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting 4
Values in Scores on a Scale · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy 0.93 22.947 Not reported Not reported Not reported Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy 3.70 9.072 Not reported Not reported Not reported Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2 5.56 14.344 Not reported Not reported Not reported Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma -11.11 NA Not reported Not reported Insufficient number of participants to calculate standard deviation. Cohort 5: Primary Central Nervous System Lymphoma -16.67 7.857 Not reported Not reported Not reported Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting -8.33 16.667 Not reported Not reported Not reported
Complete source fields classes categories measurements
group Id OG000
spread 17.070
value -4.41
group Id OG001
spread 17.898
value -5.07
group Id OG002
spread 10.244
value -6.67
comment Insufficient number of participants to calculate standard deviation.
group Id OG003
spread NA
value -8.33
group Id OG004
spread 25.685
value 8.33
group Id OG005
spread 12.108
value -7.41 denoms counts
group Id OG000
value 34
group Id OG001
value 23
group Id OG002
value 10
group Id OG003
value 1
group Id OG004
value 5
group Id OG005
value 9
units Participants
title Global Health Status: Change from baseline Day 1 categories measurements
group Id OG000
spread 14.301
value -1.26
group Id OG001
spread 18.002
value 0.00
group Id OG002
spread 17.236
value -4.17
comment Insufficient number of participants to calculate standard deviation.
group Id OG003
spread NA
value 0.00
group Id OG004
spread 11.785
value 16.67
group Id OG005
spread 14.299
value -1.85 denoms counts
group Id OG000
value 33
group Id OG001
value 19
group Id OG002
value 10
group Id OG003
value 1
group Id OG004
value 4
group Id OG005
value 9
units Participants
title Global Health Status: Change from baseline Day 29 categories measurements
group Id OG000
spread 14.778
value 5.00
group Id OG001
spread 17.547
value 7.84
group Id OG002
spread 16.457
value 4.17
comment Insufficient number of participants to calculate standard deviation.
group Id OG003
spread NA
value 0.00
group Id OG004
spread 26.788
value 13.89
group Id OG005
spread 8.784
value 9.26 denoms counts
group Id OG000
value 30
group Id OG001
value 17
group Id OG002
value 6
group Id OG003
value 1
group Id OG004
value 3
group Id OG005
value 9
units Participants
title Global Health Status: Change from baseline Day 60 categories measurements
group Id OG000
spread 14.766
value 2.47
group Id OG001
spread 22.527
value 1.28
group Id OG002
spread 17.817
value -5.95
comment Insufficient number of participants to calculate standard deviation.
group Id OG003
spread NA
value 0.00
group Id OG004
spread 41.107
value 22.22
group Id OG005
spread 8.448
value 4.63 denoms counts
group Id OG000
value 27
group Id OG001
value 13
group Id OG002
value 7
group Id OG003
value 1
group Id OG004
value 3
group Id OG005
value 9
units Participants
title Global Health Status: Change from baseline Day 90 categories measurements
group Id OG000
spread 13.685
value 6.94
group Id OG001
spread 23.332
value 1.04
group Id OG002
spread 35.635
value -13.10
comment Insufficient number of participants to calculate standard deviation.
group Id OG003
spread NA
value -16.67
group Id OG004
spread 22.048
value 25.00
group Id OG005
spread 8.607
value 2.78 denoms counts
group Id OG000
value 12
group Id OG001
value 8
group Id OG002
value 7
group Id OG003
value 1
group Id OG004
value 3
group Id OG005
value 6
units Participants
title Global Health Status: Change from baseline Day 180 categories measurements
group Id OG000
spread 20.140
value 6.25
group Id OG001
spread 9.742
value 9.72
group Id OG002
spread 26.745
value -3.33
comment Insufficient number of participants to calculate standard deviation.
group Id OG003
spread NA
value 0.00
group Id OG004
spread 22.048
value 25.00
group Id OG005
spread 9.501
value 3.33 denoms counts
group Id OG000
value 12
group Id OG001
value 6
group Id OG002
value 5
group Id OG003
value 1
group Id OG004
value 3
group Id OG005
value 5
units Participants
title Global Health Status: Change from baseline Day 270 categories measurements
group Id OG000
spread 20.337
value -6.67
group Id OG001
spread 11.664
value 3.57
group Id OG002
spread 25.909
value -12.50
comment Insufficient number of participants to calculate standard deviation.
group Id OG003
spread NA
value 0.00
group Id OG004
spread 26.788
value 30.56
group Id OG005
spread 7.454
value 3.33 denoms counts
group Id OG000
value 10
group Id OG001
value 7
group Id OG002
value 4
group Id OG003
value 1
group Id OG004
value 3
group Id OG005
value 5
units Participants
title Global Health Status: Change from baseline Day 365 categories measurements
group Id OG000
spread 18.530
value -6.48
group Id OG001
spread 26.726
value 3.57
group Id OG002
spread 24.056
value -5.56
comment Insufficient number of participants to calculate standard deviation.
group Id OG003
spread NA
value 0.00
group Id OG004
spread 47.140
value 0.00
group Id OG005
spread 9.129
value 1.67 denoms counts
group Id OG000
value 9
group Id OG001
value 7
group Id OG002
value 3
group Id OG003
value 1
group Id OG004
value 2
group Id OG005
value 5
units Participants
title Global Health Status: Change from baseline Day 545 categories measurements
group Id OG000
spread 12.975
value -11.11
group Id OG001
spread 12.638
value -4.17
group Id OG002
spread 7.979
value -6.25
comment Insufficient number of participants to calculate standard deviation.
group Id OG003
spread NA
value 0.00
group Id OG004
spread 29.463
value 20.83
group Id OG005
spread 21.916
value -2.08 denoms counts
group Id OG000
value 12
group Id OG001
value 6
group Id OG002
value 4
group Id OG003
value 1
group Id OG004
value 2
group Id OG005
value 4
units Participants
title Global Health Status: Change from baseline Day 730 categories measurements
group Id OG000
spread 20.970
value -3.33
group Id OG001
spread 21.074
value -6.09
group Id OG002
spread 11.440
value -3.33
comment Insufficient number of participants to calculate standard deviation.
group Id OG003
spread NA
value -6.67
group Id OG004
spread 19.777
value -2.67
group Id OG005
spread 14.948
value -3.70 denoms counts
group Id OG000
value 34
group Id OG001
value 23
group Id OG002
value 10
group Id OG003
value 1
group Id OG004
value 5
group Id OG005
value 9
units Participants
title Physical Functioning: Change from baseline Day 1 categories measurements
group Id OG000
spread 18.555
value -2.63
group Id OG001
spread 10.706
value -4.21
group Id OG002
spread 14.824
value -10.00
comment Insufficient number of participants to calculate standard deviation.
group Id OG003
spread NA
value 6.67
group Id OG004
spread 16.667
value -8.33
group Id OG005
spread 18.493
value -8.15 denoms counts
group Id OG000
value 33
group Id OG001
value 19
group Id OG002
value 10
group Id OG003
value 1
group Id OG004
value 5
group Id OG005
value 9
units Participants
title Physical Functioning: Change from baseline Day 29 categories measurements
group Id OG000
spread 15.135
value 3.11
group Id OG001
spread 21.275
value -0.39
group Id OG002
spread 15.587
value -4.44
comment Insufficient number of participants to calculate standard deviation.
group Id OG003
spread NA
value 0.00
group Id OG004
spread 10.184
value -2.22
group Id OG005
spread 10.062
value -2.96 denoms counts
group Id OG000
value 30
group Id OG001
value 17
group Id OG002
value 6
group Id OG003
value 1
group Id OG004
value 3
group Id OG005
value 9
units Participants
title Physical Functioning: Change from baseline Day 60 Show more (12 of 36) denoms counts
group Id OG000
value 34
group Id OG001
value 23
group Id OG002
value 10
group Id OG003
value 1
group Id OG004
value 5
group Id OG005
value 9
units Participants
description The EORTC QLQ-C30 consists of five functional scales (physical, role, emotional, cognitive, social), three symptom scales (fatigue, nausea/vomiting, pain), a global health status/health-related quality of life (HRQoL) scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). The questionnaire is scored on a 4-point Likert scale: 1 = not at all, 2 = a little, 3 = quite a bit, 4 = very much. The raw score is the average of the items contributing to the scale. The final scores are calculated via linear transformation of raw scores and range from 0 to 100. For functional scales higher scores indicate better QoL. For symptom scales and single items lower scores indicate fewer symptoms, i.e. better QoL. Baseline the last available recorded scores on or prior to the date of JCAR017 infusion. Only global health, fatigue, physical and cognitive functioning subscales were assessed.
dispersion Type Standard Deviation groups
description JCAR017 was infused at a dose of 100 x 10\^6 JCAR017-positive transfected viable T cells (50 × 10\^6 CD8+ CAR+ T cells and 50 × 10\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).
id OG000
title Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy
description JCAR017 was infused at a dose of 100 x 10\^6 JCAR017-positive transfected viable T cells (50 × 10\^6 CD8+ CAR+ T cells and 50 × 10\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).
id OG001
title Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy
description JCAR017 was infused at a dose of 100 x 10\^6 JCAR017-positive transfected viable T cells (50 × 10\^6 CD8+ CAR+ T cells and 50 × 10\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).
id OG002
title Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2
description JCAR017 was infused at a dose of 100 x 10\^6 JCAR017-positive transfected viable T cells (50 × 10\^6 CD8+ CAR+ T cells and 50 × 10\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).
id OG003
title Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma
description JCAR017 was infused at a dose of 100 x 10\^6 JCAR017-positive transfected viable T cells (50 × 10\^6 CD8+ CAR+ T cells and 50 × 10\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).
id OG004
title Cohort 5: Primary Central Nervous System Lymphoma
description JCAR017 was infused at a dose of 100 x 10\^6 JCAR017-positive transfected viable T cells (50 × 10\^6 CD8+ CAR+ T cells and 50 × 10\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).
id OG005
title Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting
param Type MEAN
population Description All participants in the JCAR017-treated set with completed baseline questionnaires and with at least one completed post-baseline questionnaire.
reporting Status POSTED
time Frame At baseline and Day 1, 29, 60, 90, 180, 270, 365, 545, and 730 post JCAR017 infusion.
title Change From Baseline in European Organisation for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30) Scores
type SECONDARY
unit Of Measure Scores on a Scale Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle